These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11759668)

  • 1. From the Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
    JAMA; 2001 Nov; 286(19):2396-7. PubMed ID: 11759668
    [No Abstract]   [Full Text] [Related]  

  • 2. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(43):960. PubMed ID: 11708594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
    JAMA; 2001 Dec; 286(23):2935-6. PubMed ID: 11787481
    [No Abstract]   [Full Text] [Related]  

  • 4. From the Centers for Disease Control and Prevention. Interim guidelines for investigation of and response to Bacillus anthracis exposures.
    JAMA; 2001 Nov; 286(20):2540-1. PubMed ID: 11763848
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of asymptomatic pregnant or lactating women exposed to anthrax.
    Committee on Obstetric Practice
    Int J Gynaecol Obstet; 2002 Jun; 77(3):293-5. PubMed ID: 12150144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax, 2001.
    JAMA; 2001 Dec; 286(21):2662-3. PubMed ID: 11763854
    [No Abstract]   [Full Text] [Related]  

  • 7. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1051-4. PubMed ID: 11808926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Oct; 50(42):909-19. PubMed ID: 11699843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From the Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
    JAMA; 2001 Nov; 286(18):2226-32. PubMed ID: 11757528
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-exposure anthrax prophylaxis.
    Med Lett Drugs Ther; 2001 Oct; 43(1116-1117):91-2. PubMed ID: 11689760
    [No Abstract]   [Full Text] [Related]  

  • 11. From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
    JAMA; 2001 Nov; 286(20):2536-7. PubMed ID: 11763846
    [No Abstract]   [Full Text] [Related]  

  • 12. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
    Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim guidelines for investigation of and response to Bacillus anthracis exposures.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):987-90. PubMed ID: 11724154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign.
    Shaffer D; Armstrong G; Higgins K; Honig P; Coyne P; Boxwell D; Beitz J; Leissa B; Murphy D
    Pharmacoepidemiol Drug Saf; 2003; 12(3):177-82. PubMed ID: 12733470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update: Investigation of bioterrorism-related anthrax, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(45):1008-10. PubMed ID: 11724158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.
    Meaney-Delman D; Zotti ME; Creanga AA; Misegades LK; Wako E; Treadwell TA; Messonnier NE; Jamieson DJ;
    Emerg Infect Dis; 2014 Feb; 20(2):. PubMed ID: 24457117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Centers of Disease Control and Prevention. Evaluation of postexposure antibiotic prophylaxis to prevent anthrax.
    JAMA; 2002 Feb; 287(6):710. PubMed ID: 11855386
    [No Abstract]   [Full Text] [Related]  

  • 18. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax.
    JAMA; 2002 Feb; 287(5):579. PubMed ID: 11838446
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-exposure anthrax prophylaxis.
    Conn Med; 2001 Dec; 65(12):721-2. PubMed ID: 11797483
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous anthrax: an overview.
    Celia F
    Dermatol Nurs; 2002 Apr; 14(2):89-92. PubMed ID: 12017087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.